Clinical Trials · NCT00532545

Bone Marker Changes With Teriparatide/Postmenopausal Osteoporosis

Name: Bone Marker Changes With Teriparatide/Postmenopausal Osteoporosis
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 4Teriparatide

Phase: Phase 4
Recruitment status: Completed
Sponsor: Eli Lilly and Company
Enrollment: 45
Start date: Apr 2003
Locations: 7 sites, Puerto Rico
Primary endpoint: To test the hypothesis that Teriparatide injections given 20 micrograms/daily subcutaneously, for one month, is able to produce reliable changes in the bone marker in a severe osteoporotic population in Puerto Rico.

View Teriparatide compound reference